This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
Spectacle lenses for myopia control provide a clear central zone and a ‘treatment’ area for myopic defocus. This study found that atropine 0.01% and glare situations had minimal impacts on visual performance when adults wore the DIMS spectacle lens. This indicates likely tolerance of the combination in children.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Orthokeratology is effective for myopia control but is it suitable for a child with trichiasis and corneal staining? This case compiles the treatment suggestions for managing a young myopic patient with trichiasis from the Facebook community, with a focus on safety.
What is the relationship between pupil size and myopia management? As the pupil controls the light input to the retina, does pupil size influence myopia risk or the response to myopia treatments? This review covers atropine’s influence on pupil size, the relationship with treatment zone size in orthokeratology, combination treatments and advice on normal outcomes.
In this case study, a child with myopia appears to have progressed 2.50D in a year. Axial length measurement provided invaluable data to validate this refractive shift – read more about the case and how the patient was managed.
Nightly use of atropine 0.01% was able to reduce myopia progression and axial elongation for Chinese children over 9 months. However, this study also found that refractive astigmatism may increase within the first 3 months of treatment as a result.
Low-dose atropine (0.05% or less) has a maximum effect on pupil size for both bright and dim light conditions within an hour of instillation, but has little to no effect on binocular vision in myopic children when used for myopia management.
Atropine 0.01% combined with orthokeratology slows axial elongation to less than 0.1mm/year over two years in Chinese children aged 6-11 years. This is the equal-longest study on this topic and first to measure potential mechanisms of pupil size and choroidal thickness. The largest effect of the combination occurred in the first 6 months.
In myopic children, interventions to slow progression are warranted to prevent the development of high myopia and subsequent pathology and also to reduce the economic burden caused by uncorrected and pathologic myopia. This IMI Report describes the latest advice on preventing the development and progression of myopia – read the summary here.
